The effects of nifedipine on platelet aggregation and plasma 6-keto-PGF1 alpha, and its interaction with indomethacin.
Pre-incubation of human platelets with nifedipine in vitro or treatment of normal volunteers with nifedipine, 30 mg daily for one week, did not alter ADP induced aggregation measured by whole blood aggregometry. 6-oxo-Prostaglandin F1 alpha remained undetectable in plasma following oral administration of nifedipine to normal volunteers. The hypotensive response to intravenous nifedipine administration was similar in spontaneously hypertensive rats pretreated with indomethacin or placebo. These results conflict with previous reports that nifedipine alters platelet aggregation and prostaglandin metabolism.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood*; D000328:Adult; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004347:Drug Interactions; D005260:Female; D006801:Humans; D006973:Hypertension / Q000378:metabolism; D007213:Indomethacin / Q000378:metabolism* / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000378:metabolism* / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D011897:Random Allocation; D051381:Rats
D015121:6-Ketoprostaglandin F1 alpha; D009543:Nifedipine; D007213:Indomethacin